Clinical Trial Update: BAX 802 in CHA With Inhibitors [Phase 3]

View source ↗

Summary

Phase 3 trial of BAX 802 in Hemophilia A was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• BAX 802

Snippet

Sponsor: Baxalta now part of Shire | Conditions: Hemophilia A | Phase 3 | Status: TERMINATED | Results posted: 2021-10-20